Buteyko Breathing Method Research

This randomized controlled trial evaluated the Buteyko breathing technique (BBT) in 68 adult patients with partially controlled or uncontrolled asthma. Participants were assigned to either a BBT intervention group or a control group receiving standard asthma care.

The BBT group completed a structured training program over several weeks and was assessed at baseline, 3 months, and 6 months. Primary outcomes included the Asthma Control Questionnaire (ACQ) and Asthma Quality of Life Questionnaire (AQLQ).

Results showed that the BBT group had significantly improved asthma control scores and quality of life compared to controls at 3 months. Functional respiratory parameters also showed favorable trends. The improvements were clinically meaningful, with effect sizes reaching the minimal clinically important difference thresholds.

This study adds to the evidence base supporting Buteyko as a legitimate adjunctive therapy for asthma management, with the advantage of being a well-designed RCT with validated outcome measures and adequate follow-up.

This randomized controlled pilot study was the first to evaluate Buteyko breathing technique specifically in children with asthma. Thirty-two children aged 6-15 with partially controlled asthma were randomized to treatment as usual (TAU) or TAU plus an intensive 5-day Buteyko training followed by 3 months of home practice.

While the primary outcome of bronchodilator reduction showed no significant between-group difference, the Buteyko group demonstrated significantly improved lung function (FEV1) both at rest and after exercise. Parents also reported significantly improved emotional function on quality-of-life measures. The study suggests Buteyko may have distinct benefits in pediatric populations, potentially improving airway function rather than just reducing medication dependence as seen in adult studies.

This BMJ Open publication outlines a protocol for a systematic review and meta-analysis of the Buteyko breathing method for asthma management. The protocol was registered with PROSPERO and follows PRISMA-P guidelines, ensuring methodological rigor.

The review targets randomized controlled trials comparing the Buteyko method against usual care, sham interventions, or other breathing techniques in people with asthma. Primary outcomes include asthma symptoms, medication use, and quality of life measures. Secondary outcomes cover lung function parameters and adverse events.

The protocol details comprehensive search strategies across multiple databases (MEDLINE, Embase, CENTRAL, and others), risk-of-bias assessment using the Cochrane tool, and planned subgroup analyses by asthma severity and intervention duration.

This protocol is important because it signals growing academic interest in rigorously evaluating the Buteyko method. By pre-registering the review methodology, the authors reduce the risk of selective reporting and establish a transparent framework for synthesizing existing evidence on Buteyko for asthma.

This Cochrane systematic review is the most comprehensive assessment of breathing exercises for adults with asthma, including an updated search through 2019. It included 22 randomized controlled trials with 2,880 participants across various breathing techniques, including the Buteyko method, yoga breathing, and physiotherapist-led programs.

The review found that breathing exercises may improve quality of life (measured by AQLQ) with a mean difference of 0.42 points, approaching the minimal clinically important difference of 0.5. Hyperventilation symptoms showed significant improvement. However, effects on lung function (FEV1, peak flow) were inconsistent across trials.

Importantly, the review noted that evidence certainty was low to moderate due to small sample sizes, heterogeneity in interventions, and risk of bias. No serious adverse events were reported, confirming the safety profile of breathing exercises as adjunctive therapy.

For the Buteyko method specifically, the included studies showed trends toward reduced bronchodilator use and improved asthma control, consistent with earlier individual trial findings. The review supports breathing exercises as a safe add-on to standard asthma treatment, while calling for larger, higher-quality trials with standardized protocols.

This single-blinded randomized controlled trial from New Zealand evaluated the Buteyko Breathing Technique in 38 asthma patients aged 18-70 over a 6-month follow-up period. The study found dramatic reductions in medication use without compromising safety.

The intervention group achieved an 85% reduction in beta-agonist use compared to 37% in controls, and a 50% reduction in inhaled steroids while controls showed no change. No adverse events were recorded in either group. Like other Buteyko trials, FEV1 did not change significantly, reinforcing that the technique reduces medication dependence and symptoms without altering objective airway function. The authors concluded Buteyko is a safe and effective asthma management approach with potential clinical and economic benefits.

This randomized controlled trial examined whether Buteyko breathing technique could reduce medication use in asthma patients compared to standard asthma education.

Participants who learned Buteyko breathing showed significant reductions in reliever medication use while maintaining asthma control, supporting the method as a complementary approach to asthma management.

This blinded randomized controlled trial from Australia was one of the earliest rigorous evaluations of Buteyko breathing techniques (BBT) for asthma management. Thirty-nine asthmatics aged 12-70 were randomized to BBT training or control classes, with assessments of medication use, lung function, ventilation, and quality of life.

The BBT group achieved large, statistically significant reductions in reliever medication and a near-significant reduction in inhaled steroids, while also reducing minute ventilation. However, objective airway measurements (peak flow and FEV1) did not change in either group. The findings suggest Buteyko works primarily by reducing hyperventilation and medication dependence rather than by altering underlying airway physiology.